Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]
- Market Cap ₹ 99.4 Cr.
- Current Price ₹ 8.83
- High / Low ₹ 15.9 / 6.40
- Stock P/E 3.58
- Book Value ₹ 9.11
- Dividend Yield 0.00 %
- ROCE 2.53 %
- ROE 4.18 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.97 times its book value
- Company has delivered good profit growth of 194% CAGR over last 5 years
Cons
- Company has a low return on equity of 3.84% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 282 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 347 | |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 313 | |
Operating Profit | -0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 | 1 | 34 |
OPM % | -25% | 20% | 40% | 33% | -40% | 0% | -12% | 46% | 18% | 4% | 10% | ||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 3 | 36 |
Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 22% | |||
0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 2 | 28 | |
EPS in Rs | 0.00 | 0.01 | 0.07 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.01 | 0.07 | -0.13 | 0.19 | 2.46 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 86% |
5 Years: | 214% |
3 Years: | 507% |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | 71% |
5 Years: | 194% |
3 Years: | 377% |
TTM: | 5757% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 34% |
3 Years: | 2% |
1 Year: | 20% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 4% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 112 |
Reserves | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -10 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123 | |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | |
Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 267 | |
Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -222 | |
-0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 222 | |
Net Cash Flow | -0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 282 | ||
Inventory Days | 2,554 | |||||||||||
Days Payable | 52 | |||||||||||
Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,784 | ||
Working Capital Days | -1,186 | -876 | 36 | 81 | 73 | 46 | 0 | 0 | 0 | 2,092 | ||
ROCE % | 120% | -67% | 0% | -40% | 133% | 25% | 10% | -13% | 3% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 Sep - Newspaper Publication of Notice of AGM of the Company
-
Board Meeting Intimation for To Take On Record And Deliberate Upon The Letter Of Intent (LOI) Received From Telexcell Trade PTE LTD, Singapore
4 Sep - Board meeting on 25 Sep 2025 to consider Telexcell LOI for up to 25% stake at ₹20/share.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
3 Sep - LOI with Telexcell (Singapore) for up to 25% equity at ₹20/share; subject to due diligence and approvals within 90 days.
-
Notice Of 33Rd Annual General Meeting Of Welcure Drugs & Pharmaceuticals Limited
2 Sep - AGM Sep 27,2025: QIP up to Rs80Cr; bonus ₹11.2358Cr; 1:10 split; FPI limit 49%.
-
Reg. 34 (1) Annual Report.
2 Sep - AGM Sept 27,2025: proposals include QIP Rs80 crore, bonus ₹11.2358Cr (1:10), 10:1 stock-split, Section186 ₹500Cr, FPI 49%.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
WDPL is engaged in the manufacture and
trade of a wide range of healthcare formulations.